Mar 4 |
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
|
Mar 1 |
Lexaria slips despite FDA nod to test blood pressure drug
|
Mar 1 |
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
|
Feb 18 |
This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year
|
Feb 16 |
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
Feb 15 |
Lexaria Bioscience stock falls as it prices its $3.6M offering
|
Feb 15 |
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
Jan 30 |
Lexaria submits IND to begin Phase 1b study of DehydraTECH-CBD
|
Jan 30 |
Lexaria's Submits Investigational New Drug Application
|
Jan 16 |
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
|